Provided by Tiger Trade Technology Pte. Ltd.

Natera

395.56
-5.0900-1.27%
Post-market: 395.560.00000.00%17:40 EDT
Volume:2.82M
Turnover:1.11B
Market Cap:56.65B
PE:-288.12
High:401.09
Open:393.02
Low:383.45
Close:400.65
52wk High:437.41
52wk Low:167.33
Shares:143.22M
Float Shares:139.00M
Volume Ratio:1.35
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3729
EPS(LYR):-1.5269
ROE:-12.54%
ROA:-8.08%
PB:31.10
PE(LYR):-259.07

Loading ...

Movement Alert|Natera Falls 3.73% in Regular Trading, Profit-Taking After Breast Cancer Phase 3 Launch

Market Focus
·
Yesterday

Natera Study of Signatera to Identify Skin Cancer Earlier Begins Enrollment

MT Newswires Live
·
Yesterday

Natera Enrolls First Patients in Signatera-Guided Melanoma Trial Evaluating Early Immunotherapy Escalation

Reuters
·
Yesterday

Natera Price Target Raised to $480.00/Share from $365.00 by Citigroup

Dow Jones
·
Yesterday

Natera Inc Stock (NTRA) Moved Down by 5.30% on Oct 6: A Full Analysis

TradingKey
·
Yesterday

Movement Alert|Natera Falls 3.04% in Regular Trading, Profit-Taking After Breast Cancer Trial Launch

Market Focus
·
Oct 06

Natera announces new data shared at ASTRO 2026 on Signatera

TIPRANKS
·
Oct 06

Natera Presents New Signatera ctDNA Studies at Astro, Highlighting Radiation Oncology Use Cases

Reuters
·
Oct 06

Movement Alert|Natera Intraday Rise 3.05%, Breast Cancer Phase 3 Trial Launch Drives Gains

Market Focus
·
Oct 06

Natera, Alliance Foundation Trials Launch Phase III Navigate Breast Cancer Study Using Signatera MRD-Guided Cdk4/6 Therapy

Reuters
·
Oct 05

Alliance Foundation Trials and Natera Announce Aft-70 Navigate: a Global, Randomized, Phase Iii Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (Serd) with Signatera™ Mrd-Guided Cdk4/6 Inhibitor Therapy in Breast Cancer

THOMSON REUTERS
·
Oct 05

Natera CEO Steven Leonard Chapman Sells USD 526,544 of Common Stock

Reuters
·
Oct 03

Natera price target raised to $475 from $360 at Guggenheim

TIPRANKS
·
Oct 01

Movement Alert|Natera Rises 3.05% in Regular Trading, RBC Raises Target Price to $460 Citing Signatera Genome Dominance Potential

Market Focus
·
Sep 30

Natera (NTRA) Receives a Buy from Bernstein

TIPRANKS
·
Sep 26

Natera's Signatera Genome Could Emerge as Dominant Clinical Offering Within Few Years, RBC Says

MT Newswires Live
·
Sep 25

RBC Raises Price Target on Natera to $460 From $350, Keeps Outperform Rating

MT Newswires Live
·
Sep 25

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Natera (NTRA) and Aveanna Healthcare Holdings (AVAH)

TIPRANKS
·
Sep 25

US Research Roundup-Chevron, Exxon Mobil, GoDaddy

Reuters
·
Sep 25

Natera, Inc. : RBC Raises Target Price to $460 from $350

THOMSON REUTERS
·
Sep 25